846 related articles for article (PubMed ID: 27350555)
61. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
[TBL] [Abstract][Full Text] [Related]
62. Lack of BRAF V600E protein expression in primary central nervous system lymphoma.
Berghoff AS; Capper D; Preusser M
Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):351-3. PubMed ID: 23235345
[TBL] [Abstract][Full Text] [Related]
63. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
[TBL] [Abstract][Full Text] [Related]
64. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
65. Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry.
Dinges HC; Capper D; Ritz O; Brüderlein S; Marienfeld R; von Deimling A; Möller P; Lennerz JK
Appl Immunohistochem Mol Morphol; 2015; 23(5):382-8. PubMed ID: 25611237
[TBL] [Abstract][Full Text] [Related]
66. Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
Schirosi L; Strippoli S; Gaudio F; Graziano G; Popescu O; Guida M; Simone G; Mangia A
BMC Cancer; 2016 Nov; 16(1):905. PubMed ID: 27863476
[TBL] [Abstract][Full Text] [Related]
67. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
[TBL] [Abstract][Full Text] [Related]
68. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.
Rössle M; Sigg M; Rüschoff JH; Wild PJ; Moch H; Weber A; Rechsteiner MP
Virchows Arch; 2013 Nov; 463(5):623-31. PubMed ID: 24085553
[TBL] [Abstract][Full Text] [Related]
69. Clinical neuropathology practice news 2-2012: BRAF V600E testing.
Capper D; Berghoff AS; von Deimling A; Preusser M
Clin Neuropathol; 2012; 31(2):64-6. PubMed ID: 22385786
[TBL] [Abstract][Full Text] [Related]
70. Desmoplastic non-infantile astrocytoma/ganglioglioma: rare low-grade tumor with frequent BRAF V600E mutation.
Chatterjee D; Garg C; Singla N; Radotra BD
Hum Pathol; 2018 Oct; 80():186-191. PubMed ID: 29902580
[TBL] [Abstract][Full Text] [Related]
71. Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E Mutation.
Leblond AL; Rechsteiner M; Jones A; Brajkovic S; Dupouy D; Soltermann A
Am J Clin Pathol; 2019 Jun; 152(1):59-73. PubMed ID: 31065676
[TBL] [Abstract][Full Text] [Related]
72. Detection of BRAF V600E Mutation in Ganglioglioma and Pilocytic Astrocytoma by Immunohistochemistry and Real-Time PCR-Based Idylla Test.
Durślewicz J; Klimaszewska-Wiśniewska A; Antosik P; Kasperska A; Grzanka D; Szylberg T; Szylberg Ł
Dis Markers; 2020; 2020():8880548. PubMed ID: 32879641
[TBL] [Abstract][Full Text] [Related]
73. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
[TBL] [Abstract][Full Text] [Related]
74. Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases.
Nielsen LB; Dabrosin N; Sloth K; Bønnelykke-Behrndtz ML; Steiniche T; Lade-Keller J
Histopathology; 2018 Apr; 72(5):814-825. PubMed ID: 29119584
[TBL] [Abstract][Full Text] [Related]
75. Gliosarcomas with the
Wang L; Sun J; Li Z; Chen L; Fu Y; Zhao L; Liu L; Wei Y; Teng L; Lu D
J Clin Pathol; 2017 Dec; 70(12):1079-1083. PubMed ID: 28775171
[TBL] [Abstract][Full Text] [Related]
76. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
[TBL] [Abstract][Full Text] [Related]
77. The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features.
Cykowski MD; Allen RA; Kanaly AC; Fung KM; Marshall R; Perry A; Stolzenberg ED; Dunn ST
J Neurooncol; 2013 Dec; 115(3):477-86. PubMed ID: 24057326
[TBL] [Abstract][Full Text] [Related]
78. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test.
Hang JF; Li AF; Chang SC; Liang WY
Histopathology; 2016 Jul; 69(1):54-62. PubMed ID: 26588428
[TBL] [Abstract][Full Text] [Related]
79. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry.
Jabbar KJ; Luthra R; Patel KP; Singh RR; Goswami R; Aldape KD; Medeiros LJ; Routbort MJ
Am J Surg Pathol; 2015 Apr; 39(4):454-61. PubMed ID: 25634750
[TBL] [Abstract][Full Text] [Related]
80. A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology.
Hatae R; Hata N; Suzuki SO; Yoshimoto K; Kuga D; Murata H; Akagi Y; Sangatsuda Y; Iwaki T; Mizoguchi M; Iihara K
Neuropathology; 2017 Jun; 37(3):191-199. PubMed ID: 27792249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
